# Oxysterols in SLOS Neurodevelopment: Pathological Role and Therapy

> **NIH NIH R01** · UNIVERSITY OF WASHINGTON · 2021 · $383,278

## Abstract

Smith-Lemli-Opitz syndrome (SLOS) is a neurodevelopmental disorder that is caused by the most common
inborn error of cholesterol biosynthesis at the step of 3β-hydroxysterol-Δ7-reductase (DHCR7). This defect
leads to decreased levels of cholesterol and accumulation of its precursor, 7-dehydrocholesterol (7-DHC), in
affected individuals. SLOS phenotype manifests as multiple congenital malformations, neurological defects,
and autistic behavior. Conventional therapy for SLOS is supplementation of cholesterol, with or without simvas-
tatin, but these approaches do not improve neurological defects in patients. Recent findings suggested oxida-
tive metabolites of 7-DHC, oxysterols, are important contributors to the pathogenesis of SLOS, but the patho-
logical roles of these oxysterols in SLOS neurodevelopment have not been systematically studied, which is the
gap that this project is expected to fill. The central hypothesis is that 7-DHC-derived oxysterols are causative
factors for neurodevelopmental defects in SLOS. The long-term goals of this project are to elucidate the con-
sequences of disrupted cholesterol homeostasis during neurodevelopment and to develop therapies that can
ameliorate the neurological defects. In Aim 1, mechanisms of action of 7-DHC-derived oxysterols in neurogen-
esis will be elucidated using neural progenitor cells (NPCs) derived from WT and Dhcr7-knock out (KO) mice
and from WT and SLOS human induced pluripotent stem cells (iPSCs). The effects of Dhcr7 KO on neurogen-
esis will be compared with the effects of 7-DHC oxysterols. Protein targets of 7-DHC oxysterols will be pulled
down using synthetic tagged analogs of these oxysterols. In Aim 2, consequences of 7-DHC oxysterols on
neural development will be determined in vivo using WT and Dhcr7-KO mouse models. The effects of Dhcr7
KO and those of oxysterols on neurogenesis in vivo will be compared using immunohistochemistry. Temporal
and spatial distribution of sterols, oxysterols, and other lipids in both WT and Dhcr7-KO brains will be analyzed
by mass spectrometry (MS) techniques, such as high-resolution ion mobility-MS and imaging MS. In Aim 3,
effectiveness of blood-brain-barrier-permeable small molecules against neurological defects in SLOS will be
evaluated using animal models and NPCs derived from SLOS iPSCs. The hypothesis here is that neurological
defects in SLOS can be ameliorated by inhibiting the formation of 7-DHC-derived oxysterols with antioxidants
and/or counteracting their effects using agonists of Hedgehog (Hh) signaling pathway because some 7-DHC
oxysterols antagonize Hh signaling. In addition, sterols, oxysterols, and other lipids in blood and fibroblast
samples of SLOS patients from an ongoing antioxidant clinical trial will be characterized, aiming to identify bi-
omarkers for assessing SLOS severity and therapy effectiveness. This project represents a new angle to
understand the molecular mechanisms underlying the neurogenesis defects in SLOS and develop ...

## Key facts

- **NIH application ID:** 10206211
- **Project number:** 5R01HD092659-05
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Libin Xu
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $383,278
- **Award type:** 5
- **Project period:** 2017-07-25 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10206211

## Citation

> US National Institutes of Health, RePORTER application 10206211, Oxysterols in SLOS Neurodevelopment: Pathological Role and Therapy (5R01HD092659-05). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10206211. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
